{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T20:41:11Z","timestamp":1786308071641,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Pharmaceuticals SpA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:06:44Z","timestamp":1773889604000},"page":"621-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries"],"prefix":"10.1016","volume":"25","author":[{"given":"NJ.","family":"Simmonds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1887-9311","authenticated-orcid":false,"given":"SC.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wosniok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0906-4440","authenticated-orcid":false,"given":"C.","family":"Haugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Charretier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Procaccianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6997","authenticated-orcid":false,"given":"L.","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.03.012_bib0001","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jcf.2021.03.002","article-title":"Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting","volume":"20","author":"Schwarz","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2026.03.012_bib0002","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2217\/fmb-2021-0150","article-title":"Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis","volume":"16","author":"Elborn","year":"2021","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jcf.2026.03.012_bib0003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Stuart Elborn","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.012_bib0004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.012_bib0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"15","author":"Elborn","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.012_bib0006","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/thoraxjnl-2021-216849","article-title":"Lung function in children with cystic fibrosis in the USA and UK: A comparative longitudinal analysis of national registry data","volume":"77","author":"Schluter","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.03.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70076","article-title":"Registry Working Group of the German CF Registry. Success of the German Cystic Fibrosis Registry","volume":"34","author":"Naehrlich","year":"2025","journal-title":"Pharmacoepidemiol Drug"},{"key":"10.1016\/j.jcf.2026.03.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur Respirat Rev"},{"key":"10.1016\/j.jcf.2026.03.012_bib0009","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3390\/pharmaceutics13122051","article-title":"Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging","volume":"13","author":"Schwarz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jcf.2026.03.012_bib0010","series-title":"European Cystic Fibrosis Society Patient Registry - ECFSPR Annual Report 2021","first-page":"2025","author":"Zolin","year":"2023"},{"key":"10.1016\/j.jcf.2026.03.012_bib0011","unstructured":"Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults). NHS; n.d. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/08\/Levofloxacin-nebuliser-solution-for-chronic-Pseudomonas-lung-infection-in-cystic-fibrosis-adults.pdf; Accessed September 28, 2025."},{"key":"10.1016\/j.jcf.2026.03.012_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pupt.2023.102214","article-title":"Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany","volume":"80","author":"Naehrig","year":"2023","journal-title":"Pulmonary Pharmacol Therapeut"},{"key":"10.1016\/j.jcf.2026.03.012_bib0013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.012_bib0014","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.012_bib0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jcf.2015.02.003","article-title":"Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study","volume":"14","author":"Thompson","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.012_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00382-2020","article-title":"Predictors of massive haemoptysis after a first episode of mild-to-moderate haemoptysis in patients with cystic fibrosis","volume":"6","author":"Pavaut","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2026.03.012_bib0017","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1378\/chest.128.2.729","article-title":"Massive Hemoptysis in Cystic Fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2026.03.012_bib0018","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/resp.12618","article-title":"Association between inhaler use and risk of haemoptysis in patients with non-cystic fibrosis bronchiectasis","volume":"20","author":"Jang","year":"2015","journal-title":"Respirology"},{"key":"10.1016\/j.jcf.2026.03.012_bib0019","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/AAC.01744-10","article-title":"Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects","volume":"55","author":"Geller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2026.03.012_bib0020","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Levofloxacin","first-page":"1","year":"2020"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T19:45:15Z","timestamp":1786304715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000573"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}